Hsu CY, et al. - Researchers ascertained if hydroxychloroquine (HCQ) treatment is associated with increased survival in patients with systemic lupus erythematosus (SLE). Lower mortality rates due to any cause were seen in the patients with SLE who received HCQ than those who did not. The augmentation of the survival benefit was possible by HCQ adherence. Compared to the control group, lower risk of mortality was seen in the HCQ group. An association of survival protective effect with HCQ adherence was noted in the subgroup analysis.